Pharmacoeconomic study of drug bisoprolol in the treatment of hypertension
Objective: To determine according to pharmacoeconomic analysis preferential drug in the treatment of hypertension among Bisoprolol derivates - Biprol, Concor and Bisogamma. Methods: A retrospective study conducted a series of pharmacoeconomic analysis: the «disease cost «, «economic modeling», «cost - effectiveness,» «sensitivity» and «budget impact analysis «. Three drugs were analyzed - Biprol, Concor and Bisogamma. For a comprehensive evaluation of the effectiveness, provided by the proportion of patients achieving target BP values, results of two studies (Belousov YU.B. et al., 2009, Shostak N.A. et al., 2008) were obtained. The prices of medicines and diagnostic tests were taken from official sources, published on by July 2011. Results: Despite comparable efficacy of all drugs, general medical costs for a patient per year were 11 167 - 13 707 rubles, and were minimal in Biprol, maximal - in Concor and middle - in the Bisogamma groups. «Cost-effectiveness» analysis set minimum value of CER in Biprol (14 500 rub.), maximal in Concor (18 000 rub.) and intermediate (15 500 rub.) in the Bisogamma group for achieving one case of target BP values during 1 year. Budget impact analysis revealed that in Russian Federation settings treatment transition Concor - Biprol during 1 year accompanied by a cash savings of 130 128 010 000 rub. and provides additional 11 629 550 patients to be treated; the corresponding figures for Concor - Bisogamma transition were - 8 453 198 patients and 99 645 267,500 of saved rubles. Sensitivity analysis showed that the oscillation of bisoprolol prices in the 100% range was accompanied by a change in the total costs from 9 234 to 14 290 rubles for 1 patient per 1 year. Conclusion: The results obtained suggest drug Biprol as a dominant alternative in the treatment of arterial hypertension among other beta-blockers studied.